Streetbeat News

Products Services

COTY

Coty Inc. (NYSE:COTY) has signed a new agreement with Italian luxury fashion house Etro to produce and distribute Etro's fragrance lines and home scent collections beyond 2040. This deal emphasizes Coty's strategy to focus on fashion-driven licenses with significant multi-category potential. The partnership aims to explore new categories and innovations to expand Etro's beauty portfolio. Earlier, Coty also secured a long-term agreement with Marni, showcasing its strong alliances within the fashion industry.

Portfolio Pulse from Nabaparna Bhattacharya

February 20, 2024 | 12:14 pm

EVGN

Syngenta Crop Protection and Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ:EVGN), have announced a partnership to discover and develop novel bio-insecticide solutions. The collaboration aims to combine Lavie Bio's technology platform with Syngenta's global R&D and commercialization capabilities.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:14 pm

CMMB

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) announced that Brazil and Israel Patent Offices have granted new patents for CM-101, its monoclonal antibody for fibro-inflammatory diseases. CM-101, targeting CCL24, is in a global Phase 2 trial for primary sclerosing cholangitis with results expected by mid-2024.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:10 pm

DFIN

Donnelley Financial (DFIN) announced it is identifying opportunities arising from new regulations, including tailored shareholder reports, and is preparing to help clients comply with upcoming regulatory changes.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:08 pm

DTIL

Precision BioSciences, Inc. (DTIL) has granted Caribou Biosciences a non-exclusive, worldwide license to use one of Precision's cell therapy patent families with CRISPR for human therapeutics. Financial terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:08 pm

ASML

Recent analyst ratings for ASML Holding (NASDAQ:ASML) show a bullish trend with an average 12-month price target of $975.6, marking a 19.53% increase from the previous target. Analysts from Wells Fargo, Susquehanna, Raymond James, and JP Morgan have raised their price targets, reflecting positive expectations for ASML's performance. The company, a leader in photolithography systems for semiconductor manufacturing, has shown strong financial performance with significant revenue growth, high net margin, and effective debt management.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 12:00 pm

PHR

Phreesia announced that new data indicates providing patients with relevant cancer-prevention information during check-in can increase screening rates. A health system's inquiry to over 87,000 patients about mammogram screenings resulted in 32% of them requesting a mammogram appointment.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:59 am

KALV

KalVista Pharmaceuticals announced that the UK's MHRA has awarded an Innovation Passport for Sebetralstat, a novel oral treatment for Hereditary Angioedema. This is the initial step in the ILAP, aimed at accelerating market access for innovative medicines.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:56 am

IBM

WIT

Wipro has introduced an enterprise AI-ready platform, utilizing IBM Watsonx, aimed at accelerating the adoption of generative AI in enterprises. This initiative is part of a broader partnership between IBM and Wipro, which includes the creation of a tech hub to assist joint clients with AI integration.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:48 am

MRK

Merck announced that the FDA has granted priority review to its application for KEYTRUDA, in combination with chemotherapy, as a treatment for primary advanced or recurrent endometrial carcinoma. This development could potentially enhance Merck's oncology portfolio and strengthen its position in the cancer treatment market.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:46 am